La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Almirall Gestione

Gestione criteri di controllo 2/4

Almirall's Il CEO è Carlos Gallardo Piqué, nominato in Jan2022, ha un mandato di 2.58 anni. possiede direttamente 0% delle azioni della società, per un valore di € 8.16K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.1 anni e 9.2 anni.

Informazioni chiave

Carlos Gallardo Piqué

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.7yrs
Proprietà del CEO	0.0004%
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	9.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15

AMMINISTRATORE DELEGATO

Carlos Gallardo Piqué (52 yo)

2.7yrs

Mandato

€50,000

Compensazione

Mr. Carlos Gallardo Piqué serves as President at Almirall S. A. since January 2024. He has been Chairman of Board at Almirall, S.A. since May 06, 2022. He serves as Chief Executive Officer at Almirall, S.A...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Carlos Gallardo Piqué	CEO, President	2.7yrs	€50.00k	0.00043% € 8.1k
Michael McClellan	CFO & Member of Management Board	4.8yrs	Nessun dato	Nessun dato
Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	no data	Nessun dato	Nessun dato
Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	no data	Nessun dato	Nessun dato
Volker Koscielny	Chief Medical Officer & Member of Management Board	4.7yrs	Nessun dato	Nessun dato
Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	3.7yrs	Nessun dato	Nessun dato
Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	3.7yrs	Nessun dato	Nessun dato
Isabel Gomes	Company Vice Secretary	2.7yrs	Nessun dato	Nessun dato
Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	2.7yrs	Nessun dato	Nessun dato
Pablo del Fraile	Senior Director of Investor Relations	no data	Nessun dato	Nessun dato
Xavier Alba	Acting CSO and Head of R&D	no data	Nessun dato	Nessun dato
Daniel Ripley Soria	Company Secretary	2.7yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

Gestione esperta: Il team dirigenziale di ALM è considerato esperto (durata media dell'incarico 3.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Carlos Gallardo Piqué	CEO, President	10.2yrs	€50.00k	0.00043% € 8.1k
Sidney Taurel	Member of Global Advisory Board-Spain	15.7yrs	Nessun dato	Nessun dato
Thomas Fulton McKillop	Independent First Vice Chairman	15.3yrs	€132.00k	Nessun dato
Enrique de Leyva Perez	Lead Independent Director	5.6yrs	Nessun dato	0.0098% € 184.8k
Karin Louise Dorrepaal	External Independent Director	11.7yrs	€122.00k	Nessun dato
Eva-Lotta Coulter	Independent Director	4yrs	Nessun dato	Nessun dato
Ruud Dobber	Independent Director	3.3yrs	Nessun dato	Nessun dato
Antonio Gallardo Torrededia	Proprietary Director	10.2yrs	€50.00k	0.000090% € 1.7k
Seth Orlow	External Independent Director	8.3yrs	Nessun dato	Nessun dato
Alexandra Kimball	Independent Director	4yrs	Nessun dato	Nessun dato

9.3yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALM sono considerati esperti (durata media dell'incarico 9.2 anni).

Almirall Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A., Annual General Meeting, May 05, 2023

Almirall, S.A. Announces Executive Changes

Almirall, S.A. Announces Executive Changes

Recent updates

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis